Cystic Fibrosis: Clinical Assets In Development
Executive Summary
The early-stage CF pipeline is full of opportunity for many companies.
You may also be interested in...
Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis
Intellectual property licensed from UCSF focuses on non-mutated, wild-type CFTR activators and inhibitors, thought to offer potential in ophthalmic, renal and gastrointestinal indications.
Vertex Plays Defense In CF With Concert Deal
Vertex is spending $160m to acquire Concert's "enhanced" version of its own blockbuster cystic fibrosis treatment Kalydeco, known as CTP-656, in a defensive move that could allow the company to simplify its dosing regimens and differentiate its products against future competition.
Cystic Fibrosis: Successes, Opportunities And Challenges
What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.